Sputnik V 75 percent effective against Omicron: Vaccine developer

Published On 2022-01-20 03:30 GMT | Update On 2022-01-20 03:30 GMT

Moscow: The effectiveness of the Sputnik V Covid-19 vaccine against the Omicron coronavirus variant is 75 per cent, Alexander Gintsburg, the head of Russia's Gamaleya Research Center, said on Tuesday.

"In the population, the effectiveness of the Sputnik V vaccine in relation to Omicron ... is 75 per cent," Gintsburg said in the Rossiya Segodnya press center, ANI reported.

The Gamaleya head added that protection against Omicron increases to 100 per cent if a person receives a Sputnik Light booster dose in six months but decreases to 56-57 per cent if revaccination is not done.

The Sputnik V effectiveness against Omicron decreases by eight times but it is still enough for protection, Gintsburg said, adding that the effectiveness of other vaccines decreases by 21 times.

Sputnik V is the world's first registered vaccine based on a well-studied human adenovirus vector platform. It has been approved for use in 71 countries with a total population of 4 billion people.

The Sputnik V vaccine is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have plagued humanity for millennia. A storage temperature of +2…+8 °C allows the vaccine to be stored in a regular refrigerator without the need to invest in additional cold chain infrastructure.

Article Source : with agency inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sputnik V 75 percent effective against Omicron: Vaccine developer

Similar News